Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 8.91 is 428% above its 2-year average of 1.69, near the high end of its 2-year range (0.00–8.91).
As of the fiscal period ended Tuesday, June 30, 2026. 339.80% above its 12-month average of 2.03.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 8.91.
DEBT TO EQUITY RATIO
8.91
DEBT TO EQUITY RATIO AVG TTM
2.03
DEBT TO EQUITY RATIO AVG 3Y
N/A
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+339.80%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 773 covered companies
CURRENT VS SECTOR MEDIAN
+8001.14%
vs the sector median at left
Turn Therapeutics Inc.
Market Cap
$346.73M
Debt to Equity Ratio
8.91
TTM Avg
2.03
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$344.04M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$349.70M
Debt to Equity Ratio
2.41
TTM Avg
0.38
3Y Avg
0.25
5Y Avg
0.25
Market Cap
$353.88M
Debt to Equity Ratio
0.55
TTM Avg
2.43
3Y Avg
1.26
5Y Avg
0.85
Market Cap
$355.36M
Debt to Equity Ratio
0.08
TTM Avg
0.08
3Y Avg
0.07
5Y Avg
0.08
Market Cap
$355.43M
Debt to Equity Ratio
0.03
TTM Avg
0.09
3Y Avg
0.09
5Y Avg
0.09
Market Cap
$359.53M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.11
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.73M | 8.91 | 2.03 | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | 0.00 | 0.00 | 0.00 | 0.00 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | 2.41 | 0.38 | 0.25 | 0.25 |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | 0.64 | 0.35 | 0.27 |
| Embecta Corp. (EMBC)vs › | $353.00M | N/A | 0.01 | 0.00 | 0.00 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | 0.55 | 2.43 | 1.26 | 0.85 |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 0.08 | 0.08 | 0.07 | 0.08 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | 0.03 | 0.09 | 0.09 | 0.09 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | 0.00 | 0.00 | 0.00 | 0.11 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | 0.00 | 0.00 | 0.00 |
Debt/Equity
8.91
Current Ratio
1.19
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 8.91 |
| 2026-03-31 | 0.98 |
| 2025-12-31 | 0.02 |
| 2025-09-30 | 0.16 |
| 2025-06-30 | 0.06 |
| 2024-06-30 | 0.00 |
